// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Visual outcomes of Descemet Membrane Endothelial Keratoplasty at a Single Surgeon United Kingdom Centre

Aleksandra Pekacka - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Conjunctival oncocytic adenocarcinoma of lacrimal gland origin

Syed Ahmed - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Clinical outcomes after intracorneal ring segment implantation for keratoconus management in corneas with apical haze

Aja Reinhold - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Keratoconus

N/A

Slow Mohs surgery for the treatment of periocular basal cell carcinomas, three and five year follow‐up

Richard Thornton - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Basal cell carcinoma

N/A

Recurrent pyogenic granuloma (Lobular Capillary Haemangioma) of the eyelid in a breast‐feeding patient

Nyaish Mansoor - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Investigating basal cell carcinoma recurrence and outcomes following surgical excision at Broomfield hospital ophthalmology department, United Kingdom

Caroline Wong - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Basal cell carcinoma

N/A

Ocular manifestations of testicular lymphoma

Abigail Hopkins - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

N/A

Subthreshold laser compared to spironolactone in treatment of chronic central serous retinopathy

Stefano Mercuri - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Spironolactone

In situ forming hydrogel for sustained intraocular drug delivery

Blessing C. Ilochonwu - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Bevacizumab

Age‐related changes in flicker sensitivity with rod‐ and cone‐enhanced stimuli

Amithavikram R. Hathibelagal - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A step towards pigmentation independent retinal vessel oximetry

Katrin Hirsch - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Do patients receiving laser treatment for sight threatening diabetic retinopathy and those under the care of a consultant led multidisciplinary diabetes specialist team have better HbA1c value than those that are not under a diabetes specialist?

Syed Ahmed - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

N/A

Investigating the role of Gli1 in the development of choroidal neovascularisation

Stephen Marry - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tamoxifen

Diabetic retinopathy outcomes in patients undergoing pancreatic transplants in West London

Maja Szymanska - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

N/A

cGAS‐STING pathway activation in murine retina

Miao Tang - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon

Clinical spectrum of atypical ocular toxoplasma chorioretinitis

Ester Carreo - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Uveitis

N/A

Review of endogenous endophthalmitis in a tertiary eye centre; can we spot the trends?

Namita Mathews - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The Influence of stereopsis on ability to perform simulated cataract surgery

Andrew Tatham - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Cataract

N/A

An evaluation of complication rates in patients undergoing the unconventional “standing” phacoemulsification procedure

Namita Mathews - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predictive value of screening tests for sight‐threatening eye disease in a UK population

John Lawrenson - European Association for Vision and Eye Research (EVER) , 2019

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Primary open angle glaucoma

N/A

Copyright © 2026. QuantiNova All rights reserved